PRFX logo

PRF Technologies Ltd.

PRFX
Healthcare|Drug Manufacturers - Specialty & Generic|IL
$0.87
+0.11 (+14.77%)
DCF Value
$6.39
Tangible Book / Share
$7.51
Cash / Share
$9.27

Analyst Consensus

Hold1 analysts
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

Rating Trend

Mar 24
1 buy · 0 hold · 0 sell
Apr 24
1 buy · 0 hold · 0 sell
May 24
1 buy · 0 hold · 0 sell
Jun 24
1 buy · 0 hold · 0 sell
Jul 24
1 buy · 0 hold · 0 sell
Aug 24
1 buy · 0 hold · 0 sell
Sep 24
2 buy · 0 hold · 0 sell
Oct 24
2 buy · 1 hold · 0 sell
Nov 24
1 buy · 1 hold · 0 sell
Dec 24
0 buy · 1 hold · 0 sell
Jan 25
0 buy · 1 hold · 0 sell
Feb 25
0 buy · 1 hold · 0 sell

Recent Rating Actions

FirmActionRatingDate
Maxim GroupdowngradeBuy →HoldOct 24, 2024
Maxim GroupmaintainBuyJun 26, 2024

Earnings History

Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Jul 2, 2026$-1.12$-612.00$7.0K$7.0K
Mar 26, 2026$-7.47$-672.00$17.0K$17.0K
Oct 1, 2025$-13.75$-134.40——
Apr 7, 2025$-13.75———
Apr 4, 2025$-15.00———
Nov 21, 2024$-18.96$-4.74——
Aug 15, 2024$-47.99$-124.80——
May 15, 2024$-326.33$-2.40$0.00—

News

PRF Technologies and Dotz Nano Sign Term Sheet for Strategic Collaboration to Expand AI-Driven Energy Optimization Offering

Proposed transaction combines PRF's DeepSolar/GridFeed™ renewable energy forecasting and storage optimization platform with Dotz's AI-driven energy management technologies, creating an expanded offering across energy consumption, generation and trading

Nov 3, 2026globenewswire.com
PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center Power

Preliminary cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026, and total liabilities of approximately $2.5 million

Oct 23, 2026globenewswire.com
Head to Head Review: Harmony Biosciences (NASDAQ:HRMY) versus PainReform (NASDAQ:PRFX)

Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and PainReform (NASDAQ: PRFX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability. Analyst Ratings This is a breakdown of recent recommendations

Oct 12, 2026defenseworld.net
PRF Technologies' GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization

IEA projects global data center electricity consumption to roughly double to 950 TWh by 2030, with consumption from AI-focused data centers expected to triple Company believes GridFeed's existing AI optimization engine is well suited to helping data center operators make better use of limited power capacity TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd.

Sep 16, 2026globenewswire.com
PainReform Ltd. (NASDAQ:PRFX) Sees Significant Decrease in Short Interest

PainReform Ltd. (NASDAQ: PRFX - Get Free Report) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 47,016 shares, a drop of 76.6% from the August 15th total of 200,670 shares. Based on an average daily trading volume, of 74,557 shares,

Sep 11, 2026defenseworld.net
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform

New structure designed to enable direct strategic investment, partnerships, and commercial collaborations GridFeed built on validated AI technology and commercial engagements with leading renewable energy companies Platform to be showcased to more than 2,500 energy-market professionals at Energy Trading Week Europe in London   TEL AVIV, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd.

Sep 9, 2026globenewswire.com
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business

FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery with patient enrollment expected in the second half of 2026

Sep 3, 2026globenewswire.com